



FORM 8 (OPD) - Renalytix plc

March 8, 2024

RNS Number : 1928G

Renalytix PLC

08 March 2024

Renalytix plc

("Renalytix plc" or the "Company")

FORM 8 (OPD)

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Full name of discloser:	Renalytix PLC
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): <i>The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.</i>	N/A
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: <i>Use a separate form for each offeror/offeree</i>	Renalytix PLC
(d) Is the discloser the offeror or the offeree?	OFFEREE
(e) Date position held: <i>The latest practicable date prior to the disclosure</i>	7 March 2024
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? <i>If it is a cash offer or possible cash offer, state "N/A"</i>	N/A

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

Class of relevant security:	0.25p ordinary shares			
	Interests		Short positions	
	Number	%	Number	%
(1) Relevant securities owned and/or controlled:	Nil	0	Nil	0
(2) Cash-settled derivatives:	Nil	0	Nil	0
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:	Nil	0	Nil	0
TOTAL:	Nil	0	Nil	0

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

(b) Rights to subscribe for new securities

Class of relevant security in relation to which subscription right exists:	NONE
Details, including nature of the rights concerned and relevant percentages:	NONE

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:			
a) Interests in ordinary shares 0.25 pence each in which the Directors of Renalytix PLC are interested (and their close relatives and related trusts):			
Renalytix PLC Director	Position	Number of 0.25p ordinary shares	Percentage of total issued share capital

			of Renalytix PLC
Christopher Mills	Non-Executive Chairman	10,072,500	10.08%
James McCullough	Chief Executive Officer	2,746,386	2.75%
Fergus Fleming	Chief Technology Officer	569,481	0.57%

b) Options held by the Directors of Renalytix PLC, their close relatives and related trusts:

Renalytix PLC Director	Position	Share Scheme	Grant Date	Expiry Date	Option Price (£)	Number of Ordinary Shares (under option)
Christopher Mills	Non-Executive Chairman	CSOP	17/11/2023	17/11/2033	£0.245	95,000
Daniel Levangie	Non-Executive Director	CSOP	17/11/2023	17/11/2033	£0.245	95,000
		CSOP	27/01/2022	27/01/2032	£4.95	40,000
Catherine Coste	Non-Executive Director	CSOP	17/11/2023	17/11/2033	£0.245	95,000
		CSOP	06/07/2023	06/07/2033	£1.025	190,000
James McCullough	Chief Executive Officer	CSOP	06/07/2023	06/07/2033	£1.025	875,017
Fergus Fleming	Chief Technology Officer	CSOP	06/07/2023	06/07/2033	£1.025	352,902
O. James Sterling	Chief Financial Officer	CSOP	06/07/2023	06/07/2033	£1.025	575,160

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding,
--

formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

(c) Attachments

Are any Supplemental Forms attached?

Supplemental Form 8 (Open Positions)	NO
Supplemental Form 8 (SBL)	NO

Date of disclosure:	8 March 2024
Contact name:	O. James Sterling
Telephone number:	+1 646-397-3970

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

For further information, please contact:

Renalytix plc
James McCullough, CEO

www.renalytix.com
Via Walbrook PR

Stifel (Nomad and Joint Broker to Renalytix)

Nicholas Moore / Nick Harland / Samira Essebiyea

Tel: 020 7710 7600

Investec Bank plc (Joint Broker)

Gary Clarence / Shalin Bhamra

Tel: 020 7597 4000

Walbrook PR Limited

Paul McManus / Alice Woodings / Charlotte Edgar

Tel: 020 7933 8780 or

renalytix@walbrookpr.com

Mob: 07980 541893 / 07407 804654 / 07884

664686

CapComm Partners

Peter DeNardo

Tel:

415-389-6400 or investors@renalytix.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

FEEUWAURSOUORAR